| |
|
PROGRAM OVERVIEW
Over the past 10 years, mortality from chronic myeloid leukemia (CML) has decreased from 2400 deaths in 1997 to 490 deaths in 2007. This decrease has been due largely to the development of BCR-ABL tyrosine kinase inhibitors (TKIs) that block the activity of the mutant BCR-ABL protein responsible for the disease. Although the first of these BCR-ABL inhibitors, imatinib, has become standard therapy for newly diagnosed patients, many patients develop resistance-conferring mutations that result in loss of response to the drug. More than 100 BCR-ABL mutations have been identified that confer varying degrees of loss of sensitivity to imatinib. Two newer BCR-ABL TKIs, dasatinib and nilotinib, are effective against most tumors bearing these mutations. Determining whether to increase imatinib dosage or switch to another agent in the case of imatinib failure or suboptimal response and, if switching agents, which of the two newer inhibitors is the most appropriate second-line therapy for an individual patient is based on several factors. These include the level of the patient’s response to imatinib, the specific BCR-ABL mutations present, and pre-existing risk factors, such as bleeding disorders, diabetes, and cardiac, pancreatic, and liver disease. In this webcast, experts in the treatment of CML discuss BCR-ABL inhibitors and weigh available choices among therapeutic options in determining the best therapy for two actual patients.
|
AGENDA
|
Introduction
Moshe Talpaz, MD |
Profiles in CML: Overview of Practice Challenges
Moshe Talpaz, MD |
Profiles in CML: Case 1
Neil P. Shah, MD, PhD |
Profiles in CML: Case 2
Michael J. Mauro, MD |
Conclusion
Moshe Talpaz, MD |
top
TARGET AUDIENCE
This CME/CE activity is designed for medical oncologists, hematologists/oncologists, hematologists, leukemia specialists, and other healthcare professionals who are involved in the management of patients with CML.
ACTIVITY GOAL
The goal of this activity is to provide clinicians with a case-based approach that facilitates competence and performance through a better understanding of BCR-ABL kinase inhibitors, methodology (hematologic, cytogenetic, and molecular responses) for early identification and monitoring of treatment failure/suboptimal responses/resistance, and treatment strategies that include alternative second-generation BCR-ABL kinase inhibitors.
top
LEARNING OBJECTIVES
- By understanding the disease progression process in CML and assay methodology, measure the hematologic, cytogenetic, and molecular responses of patients undergoing first-line treatment for CML.
- Based on BCR-ABL mutation analysis in CML patients who develop resistance to first-line treatment and on the mechanism of action, efficacy, and safety of current and emerging alternative BCR-ABL kinase inhibitors, implement optimal, personalized CML treatment strategies to maximize patient response.
top
CME Information: Physicians
Statement of Accreditation
Projects In Knowledge® is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation
Projects In Knowledge designates this educational activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
CE Information: Pharmacists
 Projects In Knowledge® is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
This activity has been planned and implemented in accordance with the ACPE Criteria for Quality and Interpretive Guidelines. The ACPE Universal Program Number assigned to the program, for 1.25 contact hour (0.125 CEU) is 052-000-09-010-H01-P.
CE Information: Nurses
Projects In Knowledge, Inc. (PIK) is an approved provider of continuing nursing education by the Delaware Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation. PIK Provider Code: 080903-PROV.
Projects In Knowledge is also an approved provider by the California Board of Registered Nursing, Provider Number CEP-15227.
This activity is approved for 1.41 nursing contact hours.
Disclaimer: Accreditation refers to educational content only and does not imply ANCC, DNA, CBRN, or PIK endorsement of any product or service.
Contract for Mutual Responsibility in CME/CE
Projects In Knowledge has developed the contract to demonstrate our commitment to providing the highest quality professional education to clinicians, and to help clinicians set educational goals to challenge and enhance their learning experience. For more information on the contract, click here. |
top
DISCLOSURE INFORMATION
The Disclosure Policy of Projects In Knowledge requires that presenters comply with the Standards for Commercial support. All faculty are required to disclose any personal interest or relationship they or their spouse/partner have with the supporters of this activity or any commercial interest that is discussed in their presentation. Any discussions of unlabeled/unapproved uses of drugs or devices will also be disclosed in the course materials.
For complete prescribing information on the products discussed during this CME/CE activity, please see your current Physicians’ Desk Reference (PDR).
Michael J. Mauro, MD, has received grant/research support from Bristol-Myers Squibb, Merck & Co, Inc, and Novartis Pharmaceuticals Corporation; is on the speakers bureau of Bristol-Myers Squibb and Novartis Pharmaceuticals Corporation; and is on the advisory board of Novartis Pharmaceuticals Corporation. Dr. Mauro will be discussing novel agents for the treatment of chronic myeloid leukemia, some or all of which may be unlabeled or unapproved for use in the treatment of patients with chronic myeloid leukemia.
Neil P. Shah, MD, PhD, is consultant for Bristol-Myers Squibb and Novartis Pharmaceuticals Corporation. Dr. Shah will not reference any unlabeled/unapproved uses of drugs or devices in his presentation.
Moshe Talpaz, MD, has received grant/research support from Ariad Pharmaceuticals, Inc, Bristol-Myers Squibb, Exelixis Inc, and Novartis Pharmaceuticals Corporation; and is on the speakers bureau of Novartis Pharmaceuticals. Dr. Talpaz will be discussing novel agents for the treatment of chronic myeloid leukemia, some or all of which may be unlabeled or unapproved for use in the treatment of patients with chronic myeloid leukemia.
Peer Reviewer has no significant relationships to disclose.
Projects In Knowledge's staff members have no significant relationships to disclose.
Conflicts of interest are thoroughly vetted by the Executive Committee of Projects In Knowledge. All conflicts are resolved prior to the beginning of the activity by the Trust In Knowledge peer review process.
The opinions expressed in this activity are those of the faculty and do not necessarily reflect those of Projects In Knowledge.
This CME/CE activity is provided by Projects In Knowledge solely as an educational service. Specific patient care decisions are the responsibility of the physician caring for the patient.
This independent CME/CE activity is supported by an educational grant from Bristol-Myers Squibb.
Projects In Knowledge is a registered trademark of Projects In Knowledge, Inc.
top
Requires Flash 8 or higher
and high-speed internet
|
|
